Ftse Mib
34.600,00
-0,65%
DAX
18.726,76
-0,21%
S&P 500
5.321,46
0,25%
NASDAQ
16.813,19
0,11%
Bitcoin
69.379,01
-2,90%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Nabriva Therapeutics PLC (NBRV) Nabriva Therapeutics PLC (NBRV) Notizie

NBRV

Nabriva Therapeutics (NBRV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NBRV
DataOraFonteTitoloSimboloCompagnia
25/10/202319:43Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:NBRVNabriva Therapeutics PLC
25/10/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NBRVNabriva Therapeutics PLC
20/10/202303:01Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NBRVNabriva Therapeutics PLC
20/10/202302:22Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:NBRVNabriva Therapeutics PLC
31/07/202314:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202323:49Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NBRVNabriva Therapeutics PLC
10/07/202322:01GlobeNewswire Inc.Arbutus Appoints Two New ExecutivesNASDAQ:NBRVNabriva Therapeutics PLC
01/06/202322:31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NBRVNabriva Therapeutics PLC
22/05/202322:02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NBRVNabriva Therapeutics PLC
15/05/202323:25Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:NBRVNabriva Therapeutics PLC
31/03/202322:30Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:NBRVNabriva Therapeutics PLC
10/01/202323:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NBRVNabriva Therapeutics PLC
06/01/202313:01GlobeNewswire Inc.Nabriva Therapeutics Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
29/11/202212:30TipRanksAnalysts Conflicted on These Healthcare Names: Nabriva (NBRV), Vir Biotechnology (VIR) and Greenwich LifeSciences (GLSI)NASDAQ:NBRVNabriva Therapeutics PLC
28/11/202213:01GlobeNewswire Inc.Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
10/11/202222:01GlobeNewswire Inc.Nabriva Therapeutics Pivoting Strategic Focus Reports Third Quarter Financial Results and Provides Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
07/11/202213:01GlobeNewswire Inc.Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022NASDAQ:NBRVNabriva Therapeutics PLC
15/09/202213:01GlobeNewswire Inc.Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock SplitNASDAQ:NBRVNabriva Therapeutics PLC
06/09/202213:01GlobeNewswire Inc.Nabriva Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:NBRVNabriva Therapeutics PLC
12/08/202212:36TipRanksH.C. Wainwright Remains a Hold on Nabriva (NBRV)NASDAQ:NBRVNabriva Therapeutics PLC
11/08/202213:01GlobeNewswire Inc.Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNASDAQ:NBRVNabriva Therapeutics PLC
03/08/202222:01GlobeNewswire Inc.Nabriva Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
20/07/202222:05GlobeNewswire Inc.Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022NASDAQ:NBRVNabriva Therapeutics PLC
18/07/202215:56Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:NBRVNabriva Therapeutics PLC
18/07/202213:01GlobeNewswire Inc.Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim PharmaceuticalsNASDAQ:NBRVNabriva Therapeutics PLC
29/06/202222:23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:NBRVNabriva Therapeutics PLC
13/05/202213:01GlobeNewswire Inc.Nabriva Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:NBRVNabriva Therapeutics PLC
05/05/202222:01GlobeNewswire Inc.Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate UpdateNASDAQ:NBRVNabriva Therapeutics PLC
05/05/202213:01GlobeNewswire Inc.Nabriva Extends Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S. Through the End of 2026NASDAQ:NBRVNabriva Therapeutics PLC
02/05/202222:05GlobeNewswire Inc.Nabriva Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Highlights on May 5, 2022NASDAQ:NBRVNabriva Therapeutics PLC
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NBRV

La tua Cronologia

LSE
DFEE
Wt Euro Sml.cap
UNSW3
STNDETH
Standard
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network